Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
Teva Pharmaceutical Industries Limited furnished an update on its expected performance for the 2025 fiscal year in connection with its presentation at the 44th Annual J.P. Morgan Healthcare Conference. On January 11, 2026, the company issued a press release outlining these expectations ahead of its January 13, 2026 conference presentation, and attached that release as an exhibit. The information is being provided to regulators for disclosure purposes and is expressly designated as furnished rather than filed under U.S. securities laws.
An officer of Teva Pharmaceutical Industries Ltd. reported selling 12,300 ordinary shares on 12/16/2025 at a weighted average price of $30.2036 per share. The filing identifies the insider as the company’s Chief Accounting Officer, and shows that 5,650 shares were beneficially owned directly after the transaction. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share. The sale was executed in multiple trades at prices ranging from $30.20 to $30.205 per share.
Teva Pharmaceutical Industries Ltd. director Roberto Mignone reported selling 77,400 Ordinary Shares of Teva on 12/16/2025 at a weighted average price of $30.2409 per share. The filing notes that Teva’s Ordinary Shares may be represented by American Depositary Shares, each currently equal to one Ordinary Share.
After this sale, the report shows Mr. Mignone with 105,315 Ordinary Shares held directly. It also shows 367,600 Ordinary Shares held of record by Swiftcurrent Master Fund Ltd., for which Bridger Management, LLC is investment adviser and Mr. Mignone is manager. Under SEC rules he may be deemed to beneficially own those shares, but he disclaims beneficial ownership except to the extent of his indirect pecuniary interest.
Bridger Management, LLC filed a Rule 144 notice to sell 150,000 American Depositary Shares of Teva Pharmaceutical Industries, using Piper Sandler & Co. as broker on the NYSE, with an aggregate market value of
These 150,000 ADS were acquired on
Teva Pharmaceutical Industries Limited has amended its senior unsecured sustainability-linked revolving credit agreement to extend the stated maturity date of the lenders’ commitments and loans by one year, from April 29, 2027 to April 29, 2028. This extension is the second one-year extension permitted under the original April 29, 2022 agreement and helps keep this revolving credit facility available for a longer period.
The amendment also updates key financial covenants. The Company’s maximum permitted leverage ratio for Q4 2025 and thereafter is set at 4.25x, with potential increases if Teva completes or starts certain material transactions. If Teva achieves Investment Grade Status and no event of default is continuing, the maximum leverage and minimum interest cover ratio covenants will no longer apply; if Investment Grade Status is later lost or an event of default occurs, these covenants will be reinstated for future testing dates.
Teva Pharmaceutical Industries executive exercises options and sells shares
On December 9, 2025, a Teva Pharmaceutical Industries Ltd. executive, identified as an officer serving as Exec. VP, European Commercial, reported multiple equity transactions. The executive exercised 100,457 stock options at an exercise price of $18.61 per share and another 15,011 stock options at an exercise price of $16.99 per share, receiving the same number of Teva ordinary shares. On the same day, the executive sold 115,468 ordinary shares at a weighted average price of $28.6757 per share, leaving 48,384 ordinary shares beneficially owned directly after the transactions. The filing notes that Teva ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries executive Mark Sabag, Executive Vice President, International Markets Commercial, reported an option exercise and related share sales. On 12/09/2025, he exercised stock options to buy 118,724 Ordinary Shares at an exercise price of $18.61 per share, increasing his directly held shares.
That same day, he sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share and an additional 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, both through multiple transactions within narrow price ranges. After these transactions, he directly owned 52,828 Ordinary Shares and held no remaining stock options from this grant. Each Ordinary Share may be represented by one American Depositary Share.
Teva Pharmaceutical Industries insider plans Rule 144 share sale. A holder has filed to sell 216,892 ordinary shares of Teva through Citigroup Global Markets on the NYSE, with an aggregate market value of $6,230,750.00 as of the notice. Teva had 1,147,282,512 ordinary shares outstanding, providing context for the size of the planned sale.
The securities to be sold were acquired in two ways: 98,168 shares were received on 03/01/2021 in a rollover transaction from Teva Pharmaceutical Industries Limited, and 118,724 shares were obtained via a cashless exercise of stock options, with cash payment dated 12/09/2025. The seller represents that they are not aware of any undisclosed material adverse information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries reported a planned sale of restricted stock under Rule 144. The filing covers the potential sale of 115,468 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $3,311,131.04. The shares relate to ordinary shares acquired on 12/09/2025 via a cashless exercise of stock options, with cash noted as the form of payment.
The filing states that the person for whose account the securities may be sold represents that they are not aware of any material adverse, non-public information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries director equity update: A Teva director reported the vesting and settlement of 4,804 restricted share units into the same number of ordinary shares on 12/02/2025, shown as an "M" (conversion) transaction. Following this transaction, the director beneficially owns 4,804 ordinary shares, held directly.
These restricted share units were originally granted on December 2, 2024 and vested on December 2, 2025. Each restricted share unit entitled the holder to receive one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share. Teva’s ordinary shares may also be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
